Pharmacokinetics of ofloxacin in Patients with Multidrug-Resistant Tuberculosis.

Park, Seung Kyu; Yoon, Young Ran; Lee, Woo Chul; Jun, Hyung Min; Shon, Ji Hong; Kim, Kyoung Ah; Park, Ji Young; Shin, Jae Gook

doi:2002.52.2.128

Tuberc Respir Dis > Volume 52(2); 2002 > Article

Original Article

Tuberculosis and Respiratory Diseases 2002;52(2):128-136.
DOI: https://doi.org/10.4046/trd.2002.52.2.128 Published online February 1, 2002.

Pharmacokinetics of ofloxacin in Patients with Multidrug-Resistant Tuberculosis.

Seung Kyu Park, Young Ran Yoon, Woo Chul Lee, Hyung Min Jun, Ji Hong Shon, Kyoung Ah Kim, Ji Young Park, Jae Gook Shin

¹Department of Chest Surgery, National Masan Tuberculosis Hospital, Korea.
²Department of Pharmacology, Inje University College of Medicine and Clinical Phamacology Center, Pusan Paik Hospital, Masan, Pusan, Korea. phyoonyr@ijnc.inje.ac.kr

Abstract

BACKGROUND
There are few studies that have reported on the pharmacokinetic(PK) disposition of fluoroquinolones in patients with multi-drug resistant tuberculosis(MDR-Tb), even though fluoroquinolones are frequentl y co-prescribed to those patients. In this study, the PK disposition of ofloxacin, a fluoroquinolone, was evaluated in patients with MDR-Tb. METHODS: Twenty patients with MDR-Tb were given 2nd line Tb drugs including ofloxacin (300mg twice a day), prothionamide, cycloserine, para-aminosalicylic acid, kanamycin, and streptomycin. The patients were grouped according to their body mass index(BMI) as an index of emaciation (group A: 18.5

Key Words: MDR-Tb, Ofloxacin, Pharmacokinetics, BMI